"Tyrosine Kinases as Druggable Targets in Cancer" Edited. by Huan Ren

This book examines a few aspects of protein tyrosine kinase (PTK) and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in tyrosine kinase inhibitors (TKIs) treatment. In this rapidly evolving field, overcoming therapeutic resistance is most challenging, and multi-targeting directs the next-generation TKIs and combination therapy as ongoing strategies in cancer treatment.

Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management.


Contents
1.Introductory Chapter: Tyrosine Kinases as Drug Targets in Cancer Treatment
2.Non-receptor Tyrosine Kinases Role and Significance in Hematological Malignancies
3.JAK, an Oncokinase in Hematological Cancer
4.Noncoding RNAs as Predictive Biomarkers of Therapeutic Response to Tyrosine Kinase Inhibitors in Metastatic Cancer
5.Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies